These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38662205)

  • 61. [Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene].
    Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY
    Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983
    [No Abstract]   [Full Text] [Related]  

  • 62. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy.
    Dima D; Hughes M; Orland M; Ullah F; Goel U; Anwer F; Raza S; Mazzoni S; Bhutani D; Williams L; Lentzsch S; Samaras C; Valent J; Chakraborty R; Khouri J
    Amyloid; 2024 Sep; 31(3):195-201. PubMed ID: 38956891
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
    DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M
    Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
    Li JM; Shen Y; Wu DP; Liang H; Jin J; Chen FY; Song YP; Song EY; Qiu XF; Hou M; Qiu ZC; Shen ZX
    Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial.
    Liu Y; Li Y; Zhang R; Yu Z; Jing Y
    Front Immunol; 2023; 14():1269163. PubMed ID: 38054008
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
    Martin MG; Augustin KM; Uy GL; Welch JS; Hladnik L; Goyal S; Tiwari D; Monahan RS; Reichley RM; Cashen AF; Stockerl-Goldstein K; Westervelt P; Abboud CN; Dipersio JF; Vij R
    Am J Hematol; 2009 Nov; 84(11):733-7. PubMed ID: 19806665
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Yuen S; Phillips TJ; Bannerji R; Marlton P; Gritti G; Seymour JF; Johnston A; Arthur C; Dodero A; Sharma S; Hirata J; Musick L; Flowers CR
    Am J Hematol; 2024 Jul; 99(7):1281-1289. PubMed ID: 38700035
    [TBL] [Abstract][Full Text] [Related]  

  • 68.
    Corradi G; Forte D; Cristiano G; Polimeno A; Ciciarello M; Salvestrini V; Bandini L; Robustelli V; Ottaviani E; Cavo M; Ocadlikova D; Curti A
    Front Immunol; 2024; 15():1386517. PubMed ID: 38812504
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia.
    Li J; Chen Y; Zhu Y; Zhou J; Xu Y; Li Y; Yu K; Pan L; Wang J; Ding J; Gu J; Zhou S; Shi J; Hong M; Xu J; Pan L; Duan L; Zhang R; Zhang S; Zhu H; Lu H; Liu P; Qiu H; Wu H; Qian S
    Oncotarget; 2015 Mar; 6(8):6448-58. PubMed ID: 25749041
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.
    Wei G; Ni W; Chiao JW; Cai Z; Huang H; Liu D
    J Hematol Oncol; 2011 Nov; 4():46. PubMed ID: 22082134
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia.
    Qian SX; Li JY; Tian T; Shen YF; Jiang YQ; Lu H; Wu HX; Zhang SJ; Xu W
    Leuk Res; 2007 Oct; 31(10):1383-8. PubMed ID: 17420048
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin T levels.
    Niitsu N; Khori M; Hayama M; Kajiwara K; Higashihara M; Tamaru J
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):697-702. PubMed ID: 15701858
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
    Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Effect of venetoclax plus chemotherapy on treatment-naive acute myeloid leukemia patients with moderate to poor cytogenetic profiles and the combination's influence on the expression of proteins of the anti-apoptoic family].
    Zhonghua Zhong Liu Za Zhi; 2024 Feb; 46(2):161-167. PubMed ID: 38418191
    [No Abstract]   [Full Text] [Related]  

  • 76. Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-stimulating Factor Therapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Study from a Single-Center.
    Kong FC; Qi L; Zhou YL; Yu M; Huang WF; Li F
    Curr Med Sci; 2023 Dec; 43(6):1151-1161. PubMed ID: 38057538
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Outcomes of CAG regimen for refractory biphenotypic acute leukemia patients.
    He GS; Zhang X; Wu DP; Sun AN; Jin ZM; Qiu HY; Miao M; Tang XW; Fu ZZ; Han Y
    Chin Med Sci J; 2009 Sep; 24(3):178-81. PubMed ID: 19848320
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
    Minakata D; Fujiwara S; Ito S; Mashima K; Umino K; Nakano H; Kawasaki Y; Sugimoto M; Yamasaki R; Yamamoto C; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial.
    Wang H; Mao L; Yang M; Qian P; Lu H; Tong H; Xie W; Zhou D; Huang X; Wang Y; Xu G; Lu Y; Wei J; Mai W; Ye X; Meng H; Shen Y; Huang J; Yu W; Sun J; Sheng J; Yan X; Jin J; Zhu HH
    Lancet Haematol; 2022 Jun; 9(6):e415-e424. PubMed ID: 35512726
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
    Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.